2008
DOI: 10.1016/j.bmcl.2007.11.115
|View full text |Cite
|
Sign up to set email alerts
|

In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
8
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 21 publications
(8 citation statements)
references
References 27 publications
0
8
0
Order By: Relevance
“…Two Distinct Grb2SH3C-Gab2 Epitope Complexes Small molecule inhibitors that bind to SH3 domains or SH3 domain interacting motifs are currently not in advanced stages of development, but some early successes with both conven-tional and in silico screens have been reported (Atatreh et al, 2008;Betzi et al, 2007;Feller and Lewitzky, 2006;Feller et al, 2003). First in vivo studies of SH3 domain interaction blockers (C) Alignment of Gab protein sequences containing the Grb2 interaction motif a (PPPRPPKP).…”
Section: Structurementioning
confidence: 99%
“…Two Distinct Grb2SH3C-Gab2 Epitope Complexes Small molecule inhibitors that bind to SH3 domains or SH3 domain interacting motifs are currently not in advanced stages of development, but some early successes with both conven-tional and in silico screens have been reported (Atatreh et al, 2008;Betzi et al, 2007;Feller and Lewitzky, 2006;Feller et al, 2003). First in vivo studies of SH3 domain interaction blockers (C) Alignment of Gab protein sequences containing the Grb2 interaction motif a (PPPRPPKP).…”
Section: Structurementioning
confidence: 99%
“…Inhibition of C-Src could target proliferation, metastasis and angiogenesis in tumours, but the concomitant inhibition of N1-Src could be detrimental to promoting neuronal differentiation of brain cancers such as medulloblastoma and/or cause side effects in the developing pediatric brain. Peptidomimetic ligands of the C-Src SH3 have been developed that potently inhibit SH3 binding to proline rich motifs in vitro 38 , but these remain to be tested on the full length kinase or in cells. Finally, N1-Src-specific SH3 domain inhibitors based on PDN1 might be efficacious in other pathological processes in which inhibition of Src signalling in neurons has shown promise, such as ischemic excitotoxicity 39 .…”
Section: Discussionmentioning
confidence: 99%
“…Benzo[h]isoquinoline scaffold appears in compounds displaying a broad range of biological activity: D1 dopamine agonists [14][15][16], serotonin (5-HT2) receptor antagonists [17][18][19], histamine (H3) receptor antagonists [20,21], inhibitors of Chk1 kinase [22] and c-Src inhibitors [23].…”
Section: Introductionmentioning
confidence: 99%